Dossier assessment
Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult patients who have at least 4 migraine days per month
Result of dossier assessment:
- Untreated and pretreated patients for whom conventional migraine prophylaxis is an option: added benefit not proven
- Patients who do not respond to any of the following drug treatments/drug classes, for whom they are unsuitable, or who do not tolerate them: metoprolol, propranolol, flunarizine, topiramate, amitriptyline, clostridium botulinum toxin type A: added benefit not proven
Project details
- Project no.
- A22-95
- Commission
- Commission awarded on 31.08.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.